divergent-paired related homeobox pseudogene 4Genealiases: []
Q-omics provides the consensus-scored DPRXP4 profile across patient tissues and cancer cell-line models. DPRXP4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, DPRXP4 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, DPRXP4 RNA expression shows 17,356 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, KIRC, and UVM as cancer lineages where DPRXP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPRXP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPRXP4 survival associations across molecular data types. DPRXP4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPRXP4 RNA expression–survival associations across cancer types. High DPRXP4 expression shows unfavorable associations in LGG, STAD, KIRC and KIRP, but favorable associations in CESC and UCEC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for DPRXP4 RNA expression.
This table summarizes DPRXP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DPRXP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPRXP4 shows higher tumor expression in KIRC, KIRP, BLCA, HNSC, LUSC and PRAD. The KIRC box plot shows higher DPRXP4 RNA expression in tumor versus normal tissue (log2 FC = +0.416, t-test p < 0.001).
This table shows molecular features associated with DPRXP4 in patient tissues and cancer cell lines. In patient samples, DPRXP4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DPRXP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
